These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 27008829)

  • 21. Biosimilar safety considerations in clinical practice.
    Choy E; Jacobs IA
    Semin Oncol; 2014 Feb; 41 Suppl 1():S3-14. PubMed ID: 24560025
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comment on "The End of Phase 3 Clinical Trials in Biosimilars Development?".
    Niazi SK
    BioDrugs; 2019 Feb; 33(1):121-123. PubMed ID: 30604391
    [No Abstract]   [Full Text] [Related]  

  • 23. Author's Reply to Webster and Woollett: "The End of Phase 3 Clinical Trials in Biosimilars Development?".
    Frapaise FX
    BioDrugs; 2018 Oct; 32(5):523. PubMed ID: 30117117
    [No Abstract]   [Full Text] [Related]  

  • 24. Preface: issues in biosimilar drug development.
    Yao B; Chi E
    J Biopharm Stat; 2014; 24(6):1137. PubMed ID: 25360866
    [No Abstract]   [Full Text] [Related]  

  • 25. Biosimilars in 3D: definition, development and differentiation.
    Abraham I; Sun D; Bagalagel A; Altyar A; Mohammed A; Tharmarajah S; MacDonald K
    Bioengineered; 2013; 4(4):203-6. PubMed ID: 23714845
    [No Abstract]   [Full Text] [Related]  

  • 26. Study design is important for ESA biosimilars.
    Pollock A; Grampp G
    Nephrol News Issues; 2015 Nov; 29(12):46-8. PubMed ID: 26677596
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Biosimilars].
    Krämer I
    Ther Umsch; 2011 Nov; 68(11):659-66. PubMed ID: 22045529
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Introduction and commentary: Biosimilars-clinical trial and safety considerations.
    Reinisch W
    Semin Arthritis Rheum; 2015 Jun; 44(6 Suppl):S1. PubMed ID: 26058548
    [No Abstract]   [Full Text] [Related]  

  • 29. Pharmacovigilance and biosimilars: considerations, needs and challenges.
    Casadevall N; Edwards IR; Felix T; Graze PR; Litten JB; Strober BE; Warnock DG
    Expert Opin Biol Ther; 2013 Jul; 13(7):1039-47. PubMed ID: 23527621
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biosimilars: impact of differences with Hatch-Waxman.
    Kowalchyk K; Crowley-Weber C
    Pharm Pat Anal; 2013 Jan; 2(1):29-37. PubMed ID: 24236968
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Regulatory and cost barriers are likely to limit biosimilar development and expected savings in the near future.
    Grabowski HG; Guha R; Salgado M
    Health Aff (Millwood); 2014 Jun; 33(6):1048-57. PubMed ID: 24889955
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New contributions to consensus on biosimilars.
    Argüelles-Arias F; Barreiro-de-Acosta M; Carballo F; Hinojosa J; Tejerina T
    Rev Esp Enferm Dig; 2014 Mar; 106(3):228-9. PubMed ID: 25007024
    [No Abstract]   [Full Text] [Related]  

  • 33. Inflammatory diseases: Integrating biosimilars into clinical practice.
    Feldman SR
    Semin Arthritis Rheum; 2015 Jun; 44(6 Suppl):S16-21. PubMed ID: 26058549
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The comparability conundrum: biosimilars in the United States, Europe and Canada.
    Courage N; Parsons A
    Food Drug Law J; 2011; 66(2):203-24, i-ii. PubMed ID: 24505840
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Monoclonal antibody: the corner stone of modern biotherapeutics.
    Xia ZN; Cai XT; Cao P
    Yao Xue Xue Bao; 2012 Oct; 47(10):1275-80. PubMed ID: 23289138
    [TBL] [Abstract][Full Text] [Related]  

  • 36. European Medicines Agency guidelines to increase the pace of biosimilar development.
    Parks L
    Bioanalysis; 2012 Nov; 4(22):2665. PubMed ID: 23346558
    [No Abstract]   [Full Text] [Related]  

  • 37. The rise of biosimilars: potential benefits and drawbacks in rheumatoid arthritis.
    Yoo DH
    Expert Rev Clin Immunol; 2014 Aug; 10(8):981-3. PubMed ID: 24961712
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Global regulatory standards for the approval of biosimilars.
    Mounho B; Phillips A; Holcombe K; Grampp G; Lubiniecki T; Mollerup I; Jones C
    Food Drug Law J; 2010; 65(4):819-37, ii-iii. PubMed ID: 24479248
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 2013 in reflection.
    Mullard A
    Nat Rev Drug Discov; 2014 Jan; 13(1):5-7. PubMed ID: 24378784
    [No Abstract]   [Full Text] [Related]  

  • 40. Biosimilars and biobetters as tools for understanding and mitigating the immunogenicity of biotherapeutics.
    Barbosa MD; Kumar S; Loughrey H; Singh SK
    Drug Discov Today; 2012 Dec; 17(23-24):1282-8. PubMed ID: 22796124
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.